Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03174353 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT03174353 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 114 participants.
The verdict
NCT03174353, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
This is a single arm investigator-initiated study designed to test the feasibility and potential efficacy of preoperative lanreotide to reduce the risk of postoperative abscess or pancreatic leak and fistula. All consenting patients undergoing planned elective pancreaticoduodenectomy or distal pancreatectomy for malignancy or suspected malignancy will be treated with a single deep subcutaneous dose of lanreotide prior to planned resection on the day of surgery. Following this intervention, care will be based on standard treatment protocols. Sixty-day mortality and morbidity will be collected for all patients.
Interventions
- DRUG Lanreotide Prefilled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2018-02-20 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03174353
The ClinicalTrials.gov registry entry for NCT03174353 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lanreotide Prefilled Syringe is the first listed.
NCT03174353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03174353 about?
NCT03174353 is a clinical study titled "A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula". This is a single arm investigator-initiated study designed to test the feasibility and potential efficacy of preoperative lanreotide to reduce the risk of postoperative abscess or pancreatic leak and fistula. All consenting patients undergoing planned elective pancreaticoduodenectomy or distal pancr...
What is the current status of trial NCT03174353?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2018-02-20. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT03174353?
The interventions under investigation include: Lanreotide Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT03174353?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.